October 14, 2025
rose-b-avatar-teal
Disability in Health Care Reporting Fellow
Happy STAT Summit week! Excited to see y’all in Boston. Still planning to come but don’t have tickets? Click here.

POLITICS

Inside the FDA, political pressure is the new norm

Andrew Harnik/Getty Images

Robert F. Kennedy Jr.’s tenure atop HHS has been marked by increasing tension between career scientists and political leaders at health agencies. That tension is nearing a breaking point at the FDA, according to interviews with more than 20 current and former agency officials, as well as legal experts.

That breaking point arrived after agency scientists received an unusual inquiry in August from the leader of the center that regulates prescription medicines to learn more about leucovorin as part of Kennedy’s bid to identify autism’s root cause by September. 

Experts say the push to approve leucovorin, a generic drug that’s mainly used to alleviate side effects of cancer treatment, as an autism treatment is a sign that the U.S. is headed toward a new era of drug regulation: one where political decisions lead, and evidence follows. More details from inside the agency from STAT’s Lizzy Lawrence.


POLITICS, AGAIN

The fallout from Friday’s ‘massacre’ at the CDC

The White House said on Friday it was cutting between 1,100 and 1,200 employees at HHS. According to people familiar with the firings, the terminations were concentrated at the CDC, with a particular focus on disease surveillance and injury prevention, but according to a union representing agency employees, more than half of the terminations have since been rescinded.

A statement yesterday from the American Federation of Government Employees Local 2883 said the firings tied to the government shutdown affected more than 1,300 CDC employees, but more than 700 were reinstated via email within 24 hours, which an HHS official attributed to coding errors in job classifications. More than 600 workers remain fired, the union said. 

The reversals included almost the entire staff of the Morbidity and Mortality Weekly Report, known as the “voice of the CDC,” which initially had been laid off. Information is still trickling out about all of the offices affected, so we will keep you updated about what the scene is once the dust settles more. For now, read my colleagues’ story about the latest turmoil to upend the nation’s top health agency.


BIOTECH

AstraZeneca, Trump strike drug pricing deal

In a bid to honor his promise to lower U.S. drug prices, President Trump on Friday said he struck a drug pricing deal with AstraZeneca

Similar to the deal the president made with Pfizer at the end of September, the British pharma company agreed to give the Medicaid program lower drug prices in line with what it offers other major developed countries and to launch new drugs at so-called most-favored nation prices. 

In exchange, the U.S. will give the company a three-year reprieve on national security-related pharmaceutical tariffs, allowing AstraZeneca time to make all of the medicines it sells in the U.S. in this country, the company said. AstraZeneca recently broke ground on a new $4.5 billion manufacturing plant in Virginia, part of its pledged $50 billion in U.S. investments.

Details of the deal were not made publicly available, but what are drug pricing experts saying about it? Read the story from STAT’s Daniel Payne and Elaine Chen.



HEALTH EQUITY

LGBTQ+ clinicians hold the line, plan for future

It would be “out of touch,” as Alex Sheldon put it, if a professional group for LGBTQ+ clinicians didn’t acknowledge at its annual meeting the way that federal forces have zeroed in on the community this year. “We have people in the room who've been targeted directly — literally themselves — by the federal administration for the care that they provide,” said Sheldon, executive director of GLMA: Health Professionals Advancing LGBTQ+ Equity. “It would be alarming, honestly, if the tone weren't slightly different than it was last year.”

Last year, everyone gathered just weeks before the presidential election took place. They knew the stakes were high, Sheldon said, but “we still couldn't possibly have anticipated the rapid descent of everything that we hold dear in LGBTQ+ health care.” This weekend, the group met again for three days of plenaries and presentations organized to balance the focus on resistance to restrictive policies with building a path toward a future with expanded, improved evidence and access to care. Security was on the premises, and many attendees seemed to have considered if there was a physical risk to showing up. But there were also drag performances and karaoke. 

GLMA’s own work has also changed over the last year. While the group had previously volunteered its medical expertise in litigation, now the group is suing the federal government itself, based on the standing of its members who have lost research grants and been unable to deliver care. In August, the group notched a win when a district court judge blocked the NIH from terminating grants focused on sexual and gender minorities. — Theresa Gaffney 


MENTAL HEALTH

California enacts safeguards for AI chatbots

California Gov. Gavin Newsom signed into law yesterday a bill that forces developers of artificially intelligent chatbots to erect safeguards for users of the technology and provides them with the right to pursue legal action against negligent developers.

The law has several provisions, including preventing chatbots from exposing minors to sexual content and developing protocols for addressing talk of suicidal ideation, suicide, or self-harm in the chat. It’s the first state to develop guardrails after months of media reports about how AI chatbots can trigger delusions, paranoia, and even suicide. It’s clear that chatbots can pose a risk to a person’s mental health, especially if they have psychosis, as I wrote about in September

Relatedly, my colleague Mario Aguilar has a scoop this morning that Lyra Health will let its members talk about their mental health with a chatbot, making it the largest company to launch a generative AI product as a part of ongoing therapy treatment. Read more here.


BUSINESS

Medicare Advantage plans shrinking coverage

For years, Medicare Advantage plans have skyrocketed in popularity with zero-dollar premiums and generous benefits. But a decade of enrollment growth could finally contract for the first time in 20 years, writes STAT’s Tara Bannow.

Private Medicare insurers are saying cuts to plans and benefits are necessary because members’ care has gotten more expensive. So when Medicare’s annual enrollment period starts Wednesday, beneficiaries will face tough choices. 

Insurers have been slashing plans and benefits for a few years now. It began after the Covid-19 pandemic, when older adults returned for procedures they’d put off during shutdowns, like hip and knee replacements. Among the plans being sold for next year, industry analysts pointed to noteworthy cuts among Elevance, UnitedHealthcare, and CVS Health, which owns Aetna. Will 2026 be the bottom? Read Tara’s story.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • They helped topple Roe v. Wade. Now their sights are set on Britain, New York Times
  • Cervical cancer could be eradicated. But not with Medicaid cuts and anti-vax politics, The 19th
  • Elon Musk is quietly expanding in the Bay Area again, starting with Neuralink, San Francisco Chronicle
  • Biden is receiving radiation and hormone therapy to treat his prostate cancer,